Rare diseases
Investigational molecules
Locations
Recruiting trials first
1 clinical trial in this condition
GermanyIn short
Recognizing lymphangiosarcoma early can make a crucial difference, but many people are unaware of the warning signs and diagnostic steps that help identify this rare and aggressive cancer.
If you have chronic swelling in your arm or leg, particularly if you have a history of breast cancer treatment, it is important to pay attention to any new changes in your skin. Lymphangiosarcoma is a rare cancer that develops in people who have had long-standing lymphedema, which is swelling caused by a blockage in the lymphatic system. While this condition is uncommon, early detection is essential because the cancer spreads quickly and has serious consequences.
Most cases of lymphangiosarcoma occur in people who have had breast cancer surgery, especially the older type of surgery called radical mastectomy, which removed lymph nodes from the armpit. When lymphangiosarcoma develops after this surgery, it is known as Stewart-Treves syndrome. However, lymphangiosarcoma can also develop in anyone with chronic lymphedema from other causes, including congenital (present from birth) lymphedema, traumatic injuries, or even parasitic infections like filariasis.
You should seek medical evaluation if you notice purple or bruised-looking areas on your swollen limb, especially if these areas feel tender or develop into sores that do not heal. These warning signs typically appear many years after the lymphedema first developed—often five to fifteen years after breast cancer surgery. The cancer most commonly affects the upper arm, forearm, elbow, and anterior chest wall.
People who have survived breast cancer for five or more years and have severe lymphedema are at higher risk for developing this condition. Around 90 percent of lymphangiosarcoma cases occur in individuals with long-standing chronic lymphedema. Women are affected more often than men, primarily because the condition is strongly linked to post-mastectomy lymphedema.
When you visit a doctor with concerning skin changes on a swollen limb, they will use several methods to determine whether you have lymphangiosarcoma. The diagnostic process begins with a careful review of your medical history and a physical examination. Your doctor will want to know about any previous surgeries, particularly breast cancer treatment, how long you have had lymphedema, and when the skin changes first appeared.
The physical examination focuses on the appearance and characteristics of any suspicious areas. Lymphangiosarcoma typically presents as a purple discoloration or a tender skin nodule on the affected limb, usually on the anterior (front) surface. As the disease progresses, it can develop into an ulcer with crusting that extends into a larger area of tissue death involving the skin and the tissue beneath it. There may also be multiple smaller spots spreading out from the original site, called satellite lesions.
The most important step in diagnosing lymphangiosarcoma is obtaining a tissue sample through a biopsy. This is the only way to definitively confirm the diagnosis. During a biopsy, a doctor removes a small piece of the suspicious tissue so it can be examined under a microscope by a specialist called a pathologist. The pathologist looks for specific characteristics of cancer cells that distinguish lymphangiosarcoma from other conditions.
The biopsy helps identify the cancer cells and also rules out other conditions that might look similar, such as recurrent breast cancer that has spread to the skin, or another type of cancer called Kaposi sarcoma. This is particularly important because treatment decisions depend on knowing exactly what type of cancer is present. The tissue examination, called histological examination, reveals that lymphangiosarcoma arises from endothelial cells, which are the cells that line blood vessels and lymphatic vessels.
After a biopsy confirms the diagnosis, doctors use various imaging tests to determine the size and extent of the tumor and whether it has spread to other parts of the body. These imaging studies are crucial because lymphangiosarcoma spreads quickly, most often to the lungs, but also to the chest wall, liver, and bones.
Several types of imaging can be used, depending on what information the doctor needs. Ultrasound uses sound waves to create pictures of soft tissues and can help assess the tumor and nearby structures. A CT scan (computed tomography scan) uses X-rays to create detailed cross-sectional images of the body and is particularly useful for detecting whether the cancer has spread to the lungs or other organs. MRI (magnetic resonance imaging) uses magnets and radio waves to produce detailed images of soft tissues and can show the extent of the tumor in the limb. PET scan (positron emission tomography) can detect areas of increased metabolic activity that might indicate cancer spread.
A chest CT scan is particularly important because lymphangiosarcoma frequently spreads to the lungs. This scan can identify bilateral (both sides) pulmonary involvement and help doctors understand the stage of the disease, which influences treatment decisions.
While imaging and biopsy are the primary diagnostic tools, doctors may also order blood tests as part of the overall evaluation. These laboratory tests do not diagnose lymphangiosarcoma directly, but they help assess your overall health, check organ function, and identify any complications that might affect treatment options. Blood tests can also help monitor your condition during and after treatment.
Because lymphangiosarcoma is so rare, many patients may be offered the opportunity to participate in clinical trials, which are research studies testing new treatments. Qualifying for a clinical trial involves additional diagnostic testing beyond what is done for standard diagnosis. These tests help researchers ensure that participants meet specific criteria and can safely receive the experimental treatment being studied.
To be considered for a clinical trial, you will typically need complete documentation of your diagnosis through biopsy and histological examination. The tissue samples may be reviewed by multiple pathologists to confirm the diagnosis according to the trial's specific requirements. This ensures that all participants truly have the condition being studied.
Clinical trials often require detailed staging information, which means knowing exactly how much the cancer has spread. This involves comprehensive imaging studies, including CT scans of the chest, abdomen, and pelvis, as well as possibly PET scans to detect any areas of cancer throughout the body. The results help determine the stage of your disease, which is often a key criterion for trial eligibility.
Blood tests are also important for clinical trial qualification. Researchers need to ensure that your organ function is adequate to handle the experimental treatment. This typically includes tests of liver function, kidney function, and blood cell counts. Some trials may require specific biomarkers or genetic testing to determine whether the experimental treatment is likely to work for your particular cancer.
Performance status assessment is another standard requirement. This involves evaluating how well you can perform daily activities and how the cancer is affecting your overall functioning. Doctors use standardized scales to measure this, and many trials only accept patients who are still able to care for themselves and maintain a reasonable level of activity.
Some trials studying targeted treatments for lymphangiosarcoma may require testing for specific molecular markers or proteins. For example, because lymphangiosarcoma cells often express certain growth factors, some trials may test for these markers to identify patients most likely to benefit from targeted therapies. This type of testing is done on the biopsy tissue and requires specialized laboratory techniques.
Documentation of previous treatments is also essential for clinical trial qualification. Researchers need detailed records of any prior surgeries, chemotherapy, or radiation therapy you have received. This helps them understand how your cancer has behaved and ensures that the experimental treatment being tested is appropriate for your situation.
Throughout the clinical trial process, repeat imaging and biopsies may be required to monitor how the cancer responds to the experimental treatment. These diagnostic procedures are built into the trial protocol and help researchers gather the data needed to determine whether the new treatment is effective.
The outlook for people with lymphangiosarcoma is unfortunately quite serious. Several factors affect how the disease will progress. The most important factor is how early the cancer is detected and treated. Lymphangiosarcoma spreads very quickly to other parts of the body, most commonly to the lungs, chest wall, liver, and bones. This rapid spread, called metastasis, makes the disease particularly challenging to treat effectively.
Even when treatment is started early, the rate of cancer coming back (recurrence) is high. This happens because the cancer cells are very aggressive and can spread through both the blood vessels and the lymphatic system to distant sites in the body. Most patients with lymphangiosarcoma will experience disease progression despite treatment.
The prognosis is generally poor, with a high recurrence rate even after aggressive treatment. Factors that influence outcomes include the size of the tumor when it is discovered, whether it has already spread to other organs, the patient's overall health and ability to tolerate treatment, and how well the cancer responds to the initial treatment. Unfortunately, effective treatment options are limited, which contributes to the challenging prognosis.
The survival statistics for lymphangiosarcoma are sobering. Most individuals survive for around 2.5 years following diagnosis. The long-term survival rate is poor, largely because of the rapid spread of the tumor throughout the body.
The five-year survival rate is very low, with less than 5 percent of patients surviving five years even with treatment that combines multiple approaches such as surgery, chemotherapy, and radiation. This means that out of 100 people diagnosed with lymphangiosarcoma, fewer than 5 will still be alive five years after diagnosis.
In patients who had radical mastectomy for breast cancer and survived at least five years, the reported incidence of developing lymphangiosarcoma ranges from 0.07 percent to 0.45 percent. While this shows that lymphangiosarcoma is rare even among people with chronic post-mastectomy lymphedema, those who do develop it face a very serious prognosis.
It is important to remember that survival statistics are based on groups of people and cannot predict exactly what will happen to any individual person. Some patients may respond better to treatment than others, and ongoing research into new therapies may improve outcomes in the future.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
